Summer 2010 | Contemporary Oncology®

Tasigna Moves to the Front-Line in CML

March 04, 2011

The FDA approved Tasigna (nilotinib) as a first-line treatment for patients with newly diagnosed Philadelphia- chromosome positive (Ph ) chronic myeloid leukemia (CML), the first new drug approved for this indication in nearly a decade.

Jevtana Approved for Advanced Prostate Cancer

March 04, 2011

The FDA approved the injectable drug Jevtana (cabazitaxel), a microtubule inhibitor, in combination with prednisone as a second-line therapy for men with advanced castrate-resistant prostate cancer